top of page


$43 billion. A staggering amount above anyone's imagination. Even a 1,000 lifetimes would not be enough to accumulate such savings. Bourla, however, can. Now, anyway. Before the Covid pandemic, Pfizer was loss-making for years. That changed when it joined hands with BioNtech and developed at a record pace an MRNA gene therapy sold as a miracle product against Sars-Cov 2, with an efficacy rate as high as 94%.

With the earnings of the billion-dollar deals, Bourla's bed was spread. He has the money cash in his drawer. The man does not make acquisitions of companies with venture capital. The totality of the shares of all the companies Pfizer has acquired since the Covid crisis have been paid in hard cash and so is Seagen Inc.

Who is Seagen?

Seagen is a global biotechnology company seeking to revolutionize cancer care. A pioneer in antibody-drug conjugates (ADCs), the company has been a leader in new cancer therapies for more than 20 years. It holds licenses for four approved cancer therapies. The combined sales reached nearly $2 billion dollars in 2022.

Bourla is a visionary. He knows there is a lot to earn in cancer drugs. By pure coincidence cancer is booming since the vaccination campaigns with its worthless mRNA product. How about that ?

All the investments in acquisitions Pfizer has made in 2021 and 2022 all happen to be biotech and pharma companies dedicated to developing treatments and drugs against diseases that " coincidentally " are all side effects of his mRNA gen therapy.

17 views0 comments


bottom of page